Results 111 to 120 of about 8,947 (178)

Ruxolitinib as second-line therapy for bronchiolitis obliterans syndrome after hematopoietic cell transplantation: a retrospective multicenter study. [PDF]

open access: yesAnn Hematol
Tu Y   +23 more
europepmc   +1 more source

Younger Age and Viral Triggers Were Associated With Post-Infectious Bronchiolitis Obliterans in French Children. [PDF]

open access: yesActa Paediatr
Mazenq J   +24 more
europepmc   +1 more source

Nintedanib in progressive bronchiolitis obliterans syndrome (BOS) grade 0p-1-2 in lung transplant recipients (INFINITIx-BOS): protocol of a French multicenter randomized controlled trial. [PDF]

open access: yesTrials
Brugière O   +10 more
europepmc   +1 more source

Identification of Surrogate Outcome Biomarkers in Lung Allograft Recipients With Bronchiolitis Obliterans: Implications for Randomized Controlled Trials. [PDF]

open access: yesTransplant Direct
Byers DE   +35 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy